GlassScriptPhysician profile
Muhammad A Mullick
NPI 1487925038
$3,105.54
in general payments reported to CMS, 2019-2025
16 companies · $74.24 in 2025
The $74.24 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $496 · 2021: $419 · 2022: $587 · 2023: $310 · 2024: $529 · 2025: $74.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $883.60 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $330.93 | 2019-2023 | Camzyos |
| Pfizer INC. | $285.16 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.22 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $220.79 | 2019-2022 | |
| Abbott Laboratories | $141.98 | 2024 | Amplatzer Amulet |
| Abbvie INC. | $139.49 | 2021-2024 | |
| Boston Scientific Corporation | $133.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Arexvy |
| Janssen Scientific Affairs, LLC | $119.97 | 2022 | |
| Bioxcel Therapeutics, INC. | $115.26 | 2024 | Igalmi |
| Merck Sharp & Dohme LLC | $99.74 | 2022-2023 | Dificid, Recarbrio, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $89.91 | 2019-2021 | |
| Allergan, INC. | $79.84 | 2020 | |
| Gilead Sciences, INC. | $30.45 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $30.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mullick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.